NVIDIA Stock Dragging Stock: Why It Roils Markets Today
NVIDIA's results grabbed headlines, but the stock moved in the opposite direction, sparking a broader market reaction...
Articles — Page 2188
Hormel (HRL) 2026 Earnings Outlook for Investors Today
As Hormel gears up for Q1 2026 disclosures, investors want a clear read on margins, demand, and cash flow. This guide...
Novocure (NVCR) 2025 Earnings Outlook and Analysis
Novocure faces a pivotal year as TTFields therapy expands and reimbursement pathways evolve. This guide breaks down w...
Record Payouts Tilt Markets: Largest Dividend Payout History
Global dividend payments in Q3 2025 surged to a record, signaling the largest dividend payout history and fueling ren...
World Holdings Seeks Reincorporation From Delaware to Texas
eXp World Holdings plans to reincorporate from Delaware to Texas, with a stockholder vote slated at the annual meetin...
Live Earnings: Will Dell Rally After Q4 Results, AI Push
Dell Technologies beat Q4 expectations and raised FY27 guidance, underscoring the surge in AI-optimized servers. As i...
Live: SoundHound AI (SOUN) Earnings Coverage Moves Markets
SoundHound AI releases its latest quarterly results, prompting a brisk market response as investors weigh growth pros...
Live Earnings: Complete Rocket Lab Coverage on RKLB
Rocket Lab posted solid Q4 FY2025 revenue above estimates, while warning that the Neutron program faces a timeline sh...
Live Earnings: Complete Zscaler Coverage and Market Reaction
Zscaler posted a strong quarter, beating revenue and EPS estimates while signaling durable ARR growth. Here are the n...
Sempra (SRE) 2025 Earnings: Q4 Call Highlights for Investors
As Sempra wraps up the 2025 fiscal year, investors want clarity on the Q4 2025 earnings trajectory. This article brea...
Software Bear Market: Amazon Buying Opportunity or Decline
Investors are weighing a possible buying opportunity against a falling knife in the software bear market: amazon. Thi...
Therapeutics (TGTX) 2025 Earnings Outlook for Investors
TG Therapeutics faces a pivotal year as it closes 2025 with a tighter focus on its flagship therapeutics portfolio an...